Related Experiment Video
Updated: Jul 31, 2026

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
Modulation of glutamate receptors: strategies for the development of novel antidepressants
1DOV Pharmaceutical, Inc Hackensack, New Jersey 07601, USA. pskolnick@dovpharm.com
Abstract:
On a biochemical level, conventional antidepressants have been shown to modulate synaptic levels of biogenic amines (i.e., serotonin, norepinephrine, and dopamine), most often by interfering with reuptake processes or inhibiting metabolism. Strategies directed at modulating glutamatergic transmission may overcome the principal limitations (i.e., delayed onset and low efficacy) that appear to be inherent to these conventional agents. In this brief overview, I summarize two glutamate-based approaches to develop novel antidepressants. These distinct and (on a cellular level) seemingly diametric strategies may converge on intracellular pathways that are also impacted upon by chronic treatment with biogenic amine based agents.
More Related Videos
Related Concept Videos
G-protein Coupled Receptors
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Antiepileptic Drugs: Glutamate Antagonists

